Radiolabeled peptides for Alzheimer's diagnostic imaging: Mini review

Current Radiopharmaceuticals

Volumn 6, Issue 4, 2013, Pages 181-191

  Barrios Lopez, Brianda ^a   Raki, Mari ^a   Bergström, Kim ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Alzheimer's diagnosis; Amyloid plaque imaging; Amyloid radiopharmaceuticals; Blood brain barrier

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; FLUORINE 18; GALLIUM 68; INDIUM 111; INSULIN RECEPTOR; IODINE 125; NANOCARRIER; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TAU PROTEIN; TECHNETIUM 99M; TETRAXETAN; TRANSFERRIN RECEPTOR;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMNESIA; AMYLOID PLAQUE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; CHROMOSOME 1; CHROMOSOME 14; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONFORMATIONAL TRANSITION; DIAGNOSTIC IMAGING; DIFFUSE LEWY BODY DISEASE; DISORIENTATION; DOSIMETRY; DRUG DELIVERY SYSTEM; EARLY DIAGNOSIS; ECHOGRAPHY; ENZYME INACTIVATION; FLUORESCENCE IMAGING; FRONTOTEMPORAL DEMENTIA; GLIOSIS; GLUCOSE TRANSPORT; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LANGUAGE DISABILITY; LIPOPHILICITY; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; MOLECULAR WEIGHT; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGE DISPLAY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BENZOTHIAZOLES; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; NANOPARTICLES; NEUROFIBRILLARY TANGLES; NEUROIMAGING; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84893484390     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471006666131126222835     Document Type: Review

References (78)

1. Salomone, S.; Caraci, F.; Leggio, G. M.; Fedotova, J.; Drago, F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol., 2012, 73, 504-517.
2. Ono, M.; Saji, H. Molecular Approaches to the Treatment, Prophylaxis, and Diagnosis of Alzheimer's Disease: Novel PET/SPECT Imaging Probes for Diagnosis of Alzheimer's Disease. J. Pharmacol. Sci., 2012, 118, 338-344.
3. Gelosa, G.; Brooks, D. J. The prognostic value of amyloid imaging. Eur. J. Nucl. Med. Mol. Imaging., 2012, 39, 1207-1219.
4. Alam, M. I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40, 385-403.
5. Malakoutikhah, M.; Teixido, M.; Giralt, E. Shuttle-Mediated Drug Delivery to the Brain. Angew. Chem., 2011, 50, 7998-8014.
6. Pardridge, W. M. Biopharmaceutical drug targeting to the brain. J. Drug Target, 2010, 18, 157-167.
7. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis., 2010, 37, 48-57.
8. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther., 2008, 324, 1064-1072.
9. Biddlestone-Thorpe, L.; Marchi, N.; Guo, K.; Ghosh, C.; Janigro, D.; Valerie, K.; Yang, H. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv. Drug Deliv. Rev., 2012, 64, 605-613.
10. Chen, Y.; Liu, L Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev., 2012, 64, 640-665.
11. Abbott, N. J.; Patabendige, A. A. K.; Dolman, D. E. M.; Yusof, S. R.; Begley, D. Structure and function of the blood-brain barrier. J. Neurobiol. Dis., 2010, 37, 13-25.
12. Minati, L.; Edginton, T.; Bruzzone, M. G.; Giaccone, G. Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. Am. J. Alzheimers Dis. Other Dement., 2009, 24, 95-121.
13. McKhann G. M.; Knopmanc D. S.; Chertkow H.; Hyman B. T.; Jack Jr C. R.; Kawas C. H.; Klunk W. E.; Koroshetz W. J.; Manly J. J.; Richard Mayeux R.; Mohs R. C.; Morris J. C.; Rosso M. N.; Scheltens P.; Carrillo M. C.; Thies B.; Weintraub S.; and Phelps C. H. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement., 2011, 7, 263-269.
14. Shahani, N.; Subramaniam, S.; Wolf, T.; Tackenberg, C.; Brandt, R. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J. Neurosci., 2006, 26, 6103-6114.
15. Carter, M. D.; Simms, G. A.; Weaver, D. F. Alzheimer's diseaserelevant tau constructs in organotypic hippocampal slices. Clin. Pharmacol. Ther., 2010, 88, 475-486.
16. Candela, P.; Gosselet, F.; Saint-Pol, J.; Sevin, E.; Boucau, M.; Boulanger, E.; Cecchelli, R.; Fenart, L. Apical-to-Basolateral Transport of Amyloid-beta Peptides through Blood-Brain Barrier Cells is Mediated by the Receptor for Advanced Glycation EndProducts and is Restricted by P-Glycoprotein. J. Alzheimers Dis., 2010, 22, 849-859.
17. Pithadia, A. S.; Lim, M. H. Metal-associated amyloid-beta species in Alzheimer's disease. Curr. Opin. Chem. Biol., 2012, 16, 67-73.
18. Nordberg, A. Amyloid imaging in Alzheimer's disease. Neuropsychologia., 2008, 46, 1636-1641.
19. Bolognin, S.; Drago, D.; Messori, L.; Zatta, P. Chelation Therapy for Neurodegenerative Diseases. Med. Res. Rev., 2009, 29, 547-570.
20. Nordberg, A.; Rinne, J. O.; Kadir, A.; Langstrom, B. The use of PET in Alzheimer disease. Nat. Rev. Neurol., 2010, 6, 78-87.
21. Sharma, S.; Ebadi, M. SPECT neuroimaging in translational research of CNS disorders. Neurochem. Int., 2008, 52, 352-362.
22. Kung, H. F. The beta-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing. ACS Med. Chem. Lett., 2012, 3, 265-267.
23. Furst, A. J.; Kerchner, G. A. From Alois to Amyvid Seeing Alzheimer disease. Neurology, 2012, 79, 1628-1629.
24. Sabbagh, M.; Seibyl, J.; Akatsu, H.; Yasauomi, O.; Beach, T.; Charney, A.; Barthel, H.; Senda, K.; Murayama, S.; Ishii, K.; Leverenz, J.; Ghetti, B.; Ironside, J.; Roth, K.; Hoffman, A.; Schulz-Schaeffer, W.; Reininger, C.; Sabri, O. Results of a Multicentre Phase 3 Trial on Florbetaben for beta-Amyloid Brain PET in Alzheimer Disease. Neurology, 2012, 79, E89-E89.
25. Fodero-Tavoletti, M. T.; Brockschnieder, D.; Villemagne, V. L.; Martin, L.; Connor, A. R.; Thiele, A.; Berndt, M.; McLean, C. A.; Krause, S.; Rowe, C. C.; Masters, C. L.; Dinkelborg, L.; Dyrks, T.; Cappai, R. In vitro characterization of [F-18]-florbetaben, an A beta imaging radiotracer. Nucl. Med. Biol., 2012, 39, 1042-1048.
26. Cselenyi, Z.; Jonhagen, M. E.; Forsberg, A.; Halldin, C.; Julin, P.; Schou, M.; Johnstrom, P.; Varnas, K.; Svensson, S.; Farde, L. Clinical Validation of F-18-AZD4694, an Amyloid-beta-Specific PET Radioligand. J. Nucl. Med., 2012, 53, 415-424.
27. Vandenberghe, R.; Nelissen, N.; Salmon, E.; Ivanoiu, A.; Hasselbalch, S.; Andersen, A.; Korner, A.; Minthon, L.; Brooks, D. J.; Van Laere, K.; Dupont, P. Binary classification of F-18-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. Neuroimage, 2013, 64, 517-525.
28. Funke, S. A.; Willbold, D. Mirror image phage display-a method to generate D-peptide ligands for use in diagnostic or therapeutical applications. Mol. Biosyst., 2009, 5, 783-786.
29. Malavolta, L.; Cabral, F. R.; Fernel, L.; Conterras, G.; Ringheim, A. M.; Bressan, R. A. Use of peptides combine with nanotechnology and molecular imaging new tools for diagnosis and treatment of neuropsychiatric disorders. Rev. Bras. Psiquiatr., 2009, 31, 300-302.
30. McGonigle, P. Peptide therapeutics for CNS indications. Biochem. Pharmacol., 2012, 83, 559-566.
31. Gronwall, C.; Jonsson, A.; Lindstrom, S.; Gunneriusson, E.; Stahl, S.; Herne, N. Selection and characterization of affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol., 2007, 128, 162-183.
32. Permanne, B.; Adessi, C.; Saborio, G.; Fraga, S.; Frossard, M.; Van Dorpe, J.; Dewachter, I.; Banks, W.; Van Leuven, F.; Soto, C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J., 2002, 16, 860-864.
33. Granic, I.; Masman, M. F.; Mulder, C.; Nijholt, I. M.; Naude, P. J. W.; de Haan, A.; Borbely, E.; Penke, B.; Luiten, P. G. M.; Eisel, U. L. M. LPYFDa Neutralizes Amyloid-beta-Induced Memory Impairment and Toxicity J. Alzheimers Dis., 2010, 19, 991-1005.
34. Watanabe, K.; Nakamura, K.; Akikusa, S.; Okada, T.; Kodaka, M.; Konakahara, T.; Okuno, H. Inhibitors of fibril formation and cytotoxicity of beta-amyloid peptide composed of KLVFF recognition element and flexible hydrophilic disrupting element. Biochem. Biophys. Res. Commun., 2002, 290, 121-124.
35. Orner, B. P.; Liu, L.; Murphy, R. M.; Kiessling, L. L. Phage display affords peptides that modulate beta-amyloid aggregation. J. Am. Chem. Soc., 2006, 128, 11882-11889.
36. Wang, F.; Zhou, X.; Yang, Q.; Xu, W.; Wang, F.; Chen, Y.; Chen, G. Peptide that binds specifically to the beta-Amyloid of Alzheimer's disease: Selection and assessment of Anti-beta-Amyloid neurotoxic effects. PLoS One., 2011, 6, e27649.
37. van Groen, T.; Kadish, I.; Wiesehan, K.; Funke, S. A.; Willbold, D. In vitro and in vivo staining characteristics of small, fluorescent, A beta 42-Binding D-Enantiomeric Peptides in Transgenic AD Mouse Chem. Med. Chem., 2009, 4, 276-282.
38. Jahan, M.; Nag, S.; Krasikova, R.; Weber, U.; Muhs, A.; Pfeifer, A.; Spenger, C.; Willbold, D.; Gulyas, B.; Halldin, C. Fluorine-18 labeling of three novel D-peptides by conjugation with Nsuccinimidyl-4-[F-18]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. Nucl. Med. Biol., 2012, 39, 315-323.
39. Funke, S. A.; Bartnik, D.; Glueck, J. M.; Piorkowska, K.; Wiesehan, K.; Weber, U.; Gulyas, B.; Halldin, C.; Pfeifer, A.; Spenger, C.; Muhs, A.; Willbold, D. Development of a small D-enantiomeric Alzheimer's Amyloid-beta binding peptide ligand for future in vivo imaging applications. PLoS One., 2012, 7, e41457.
40. Fani, M.; Maecke, H. R. Radiopharmaceutical development of radiolabelled peptides. Eur. J. Nucl. Med. Mol. Imaging., 2012, 39, 11-30.
41. Koopmans, K. P.; Glaudemans, A. W. J. M. Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur. J. Nucl. Med. Mol. Imaging., 2012, 39, 4-10.
42. Sabbagh, J. J.; Kinney, J. W.; Cummings, J. L. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol. Aging., 2013, 34, 169-183.
43. Nordberg, A. PET imaging of amyloid in Alzheimer's disease. The LANCET Neurology, 2004, 3, 519-527.
44. Azzazy, H.; Mansour, M.; Kazmierczak, S. Nanodiagnostics: A new frontier for clinical laboratory medicine. Clin. Chem., 2006, 52, 1238-1246.
45. Kulkarni, P. V.; Roney, C. A.; Antich, P. P.; Bonte, F. J.; Raghu, A. V.; Aminabhavi, T. M. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2010, 2, 35-47.
46. Gilmore, J. L.; Yi, X.; Quan, L.; Kabanov, A. V. Novel nanomaterials for clinical neuroscience. J. Neuroimmune Pharm., 2008, 3, 83-94.
47. Bhaskar, S.; Tian, F.; Stoeger, T.; Kreyling, W.; de la Fuente, J. M.; Grazu, V.; Borm, P.; Estrada, G.; Ntziachristos, V.; Razansky, D. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part. Fibre Toxicol., 2010, 7, 3-7.
48. Pardridge, W. A. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers. Dement., 2009, 5, 427-432.
49. Sumbria, R. K.; Boado, R. J.; Pardridge, W. M. Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated A beta peptide radiopharmaceutical conjugated to an IgG-Avidin fusion protein. Bioconjug. Chem., 2012, 23, 1318-1321.
50. Kogan, M. J.; Olmedo, I.; Hosta, L.; Guerrero, A. R.; Cruz, L. J.; Albericio, F. Peptides and metallic nanoparticles for biomedical applications. Nanomedicine., 2007, 2, 287-306.
51. Sahni, J. K.; Doggui, S.; Ali, J.; Baboota, S.; Dao, L.; Ramassamy, C. J. Controlled Release, 2011, 152, 208-231.
52. Fazil, M.; Shadab; Baboota, S.; Sahni, J. K.; Ali, J. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future. J. Drug Target., 2012, 20, 97-113.
53. Andrieux, K.; Couvreur, P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1, 463-474.
54. Wong, H. L.; Wu, X. Y.; Bendayan, R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev., 2012, 64, 686-700.
55. Martin-Banderas, L.; Holgado, M. A.; Venero, J. L.; Alvarez-Fuentes, J.; Fernandez-Arevalo, M. Nanostructures for drug delivery to the brain. Curr. Med. Chem., 2011, 18, 5303-5321.
56. Nunes, A.; Al-Jamal, K. T.; Kostarelos, K. Therapeutics, imaging and toxicity of nanomaterials in the central nervous system. J. Controlled Release, 2012, 161, 290-306.
57. Glass, D. J.; Arnold, S. E. Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology. Alzheimers. Dement., 2012, 8, 343-351.
58. Banks, W. A. Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease. BMC Neurosci., 2008, 9, S2.
59. Gomazkov, O. A. Neurotrophins: The therapeutic potential and concept of minipeptides. Neurochem. J., 2012, 6, 163-172.
60. Laurent, S.; Ejtehadi, M. R.; Rezaei, M.; Kehoe, P. G.; Mahmoudi, M. Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease. RSC Adv., 2012, 2, 5008-5033.
61. Mori, T.; Maeda, J.; Shimada, H.; Higuchi, M.; Shinotoh, H.; Ueno, S.; Suhara, T. Molecular imaging of dementia. Psychogeriatrics., 2012, 12, 106-114.
62. Small, G. W.; Siddarth, P.; Kepe, V.; Ercoli, L. M.; Burggren, A. C.; Bookheimer, S. Y.; Miller, K. J.; Kim, J.; Lavretsky, H.; Huang, S.; Barrio, J. R. Prediction of cognitive decline by positron emission tomography of Brain Amyloid and Tau. Arch. Neurol., 2012, 69, 215-222.
63. Koffie, R. M.; Farrar, C. T.; Saidi, L.; William, C. M.; Hyman, B. T.; Spires-Jones, T. L. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc. Natl. Acad. Sci., 2011, 108, 18837-18842.
64. Wengenack, T.; Curran, G.; Poduslo, J. Targeting Alzheimer amyloid plaques in vivo. Nat. Biotechnol., 2000, 18, 868-872.
65. Marshall, J.; Stimson, E.; Ghilardi, J.; Vinters, H.; Mantyh, P.; Maggio, J. Noninvasive Imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug. Chem., 2002, 13, 276-284.
66. Mackic, J.; Bading, J.; Ghiso, J.; Walker, L.; Wisniewski, T.; Frangione, B.; Zlokovic, B. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vasc. Pharmacol., 2002, 38, 303-313.
67. Wadghiri, Y.; Sigurdsson, E.; Sadowski, M.; Elliott, J.; Li, Y.; Scholtzova, H.; Tang, C.; Aguinaldo, G.; Pappolla, M.; Duff, K.; Wisniewski, T.; Turnbull, D. Detection of Alzheimer's amyloid in Transgenic mice using magnetic resonance microimaging. Magn. Reson. Med., 2003, 50, 293-302.
68. Poduslo, J.; Curran, G.; Peterson, J.; McCormick, D.; Fauq, A.; Khan, M.; Wengenack, T. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry, 2004, 43, 6064-6075.
69. Gulyas, B.; Spenger, C.; Beliczai, Z.; Gulya, K.; Kasa, P.; Jahan, M.; Jia, Z.; Weber, U.; Pfeifer, A.; Muhs, A.; Willbold, D.; Halldin, C. Distribution and binding of F-18-labeled and I-125-labeled analogues of ACI-80, a prospective molecular imaging biomarker of disease: A whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer's disease patients. Neurochem. Int., 2012, 60, 153-162.
70. Kurihara, A.; Pardridge, W. A beta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: In-111 chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjug. Chem., 2000, 11, 380-386.
71. Lee, H.; Pardridge, W. Drug targeting to the brain using avidinbiotin technology in the mouse (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). J. Drug Target., 2000, 8, 413-424.
72. Agyare, E. K.; Curran, G. L.; Ramakrishnan, M.; Yu, C. C.; Poduslo, J. F.; Kandimalla, K. K. Development of a smart nanovehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm. Res., 2008, 25, 2674-2684.
73. Kulkarni, P. V.; Roney, C. R.; Arora, V.; Bennett, M.; Antich, P. P.; Bonte, F. J. Radiolabled polymeric nanoparticles for imaging Alzheimer's plaques in a mouse model of Alzheimer's disease (AD). Application of Accelerators in Research and Industry, 2009, 1099, 492-495.
74. Larbanoix, L.; Burtea, C.; Laurent, S.; Van Leuven, F.; Toubeau, G.; Vander Elst, L.; Muller, R. N. Potential amyloid plaquespecific peptides for the diagnosis of Alzheimer's disease. Neurobiol. Aging., 2010, 31, 1679-1689.
75. Larbanoix, L.; Burtea, C.; Ansciaux, E.; Laurent, S.; Mahieu, I.; Elst, L. V.; Muller, R. N. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library. Peptides, 2011, 32, 1232-1243.
76. Yang, J.; Wadghiri, Y. Z.; Hoang, D. M.; Tsui, W.; Sun, Y.; Chung, E.; Li, Y.; Wang, A.; de Leon, M.; Wisniewski, T. Detection of amyloid plaques targeted by USPIO-A beta 1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage, 2011, 55, 1600-1609.
77. Koffie, R. M.; Farrar, C. T.; Saidi, L.; William, C. M.; Hyman, B. T.; Spires-Jones, T. L. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc. Natl. Acad. Sci., 2011, 108, 18837-18842.
78. Guerrero, S.; Raul Herance, J.; Rojas, S.; Mena, J. F.; Domingo Gispert, J.; Acosta, G. A.; Albericio, F.; Kogan, M. J. Synthesis and in vivo evaluation of the biodistribution of a F-18-Labeled conjugate Gold-Nanoparticle-Peptide with potential biomedical application. Bioconjug. Chem., 2012, 23, 399-408.